HER2-NEGATIVE BREAST CANCER

This study tests whether taking hormone-blocking pills for 6 months before surgery helps remove all cancer cells in one piece for women with early-stage, estrogen-positive breast cancer. Eight postmenopausal women with low-risk tumors are participating. The goal is to see if this…

This study tests a drug called alpelisib combined with standard hormone therapy for people with a specific type of advanced breast cancer (HR+/HER2- with a PIK3CA mutation) whose cancer has worsened on hormone therapy alone. About 44 participants will take alpelisib daily along w…

This study tests whether adding a special heat treatment called modulated electro-hyperthermia to standard chemotherapy can shrink tumors more effectively in women with HER2-negative breast cancer. About 71 participants with stage II-III breast cancer will receive either chemo al…

This study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA or PALB2 gene mutations and early-stage breast cancer. The goal is to see if the treatment shrinks tumors and boosts immune activity. 62 participants are enrolled, and the study is act…

This phase 3 trial tests whether the drug sacituzumab govitecan can prevent breast cancer from coming back in people with HER2-negative breast cancer who still have cancer cells after standard chemotherapy before surgery. About 1,300 participants will receive either the new drug …

This study tests a new drug called onvansertib combined with standard chemotherapy (paclitaxel) in people with triple-negative breast cancer that has spread to other parts of the body. About 50 adults with advanced disease are participating to see if the combination is safe and c…

This study tests a new drug called NUV-1511 in adults with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors. The study includes people with certain breast, prostate, pancreatic, and ovarian can…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This phase 3 study tests whether a combination of two hormone-blocking drugs (fulvestrant and anastrozole) works better than anastrozole alone to shrink estrogen receptor-positive breast cancer before surgery. About 1,473 postmenopausal women with stage II or III breast cancer wi…

This early-stage trial tests a radioactive drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug targets cancer cells that have a protein called SSTR on their surface. The study aims to find t…

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a certain type of advanced breast cancer (HR+/HER2-) live longer without the disease getting worse. About 110 participants will receive either the drug alone or the combination. Th…

This study looks at whether a simple blood test that tracks cancer DNA (ctDNA) can help doctors decide when to switch treatments for people with stage IV breast cancer. The goal is to see if changing therapy earlier, based on the blood test, can keep the cancer under control long…